WeVote

Bill

Bill

SB 219

MEDICAL PSILOCYBIN ACT

2025 Regular Session Introduced by Craig Brandt and 4 co-sponsors

New Mexico legalized medical psilocybin for mental health treatment in licensed facilities, creating the first comprehensive state regulatory framework for psychedelic-assisted therapy.

Signed
0
WeVote Research Nonpartisan
Bill Summary · SB 219

Legislative bill overview

SB 219 establishes New Mexico's Medical Psilocybin Act, creating a regulated program allowing qualified patients with certain mental health conditions to access psilocybin under clinical supervision. The bill sets up licensing requirements for treatment centers, practitioner qualifications, and patient eligibility criteria while maintaining criminal penalties for unlicensed distribution.

Why is this important

This makes New Mexico one of the earliest states to legalize psilocybin for medical use, potentially offering therapeutic options for treatment-resistant depression, PTSD, and other conditions where traditional medications have failed. It reflects broader medical and scientific reassessment of psychedelic compounds' therapeutic potential, with implications for mental health treatment access and pharmaceutical regulation nationwide.

Potential points of contention

  • Federal-state legal conflict: Psilocybin remains a Schedule I controlled substance federally, creating liability and enforcement uncertainty for practitioners and facilities participating in the program
  • Access and equity concerns: Medical psilocybin programs typically require substantial out-of-pocket costs, raising questions about whether benefits will reach low-income patients or primarily serve affluent populations
  • Clinical safety framework: Debate over adequacy of training standards, supervision protocols, and long-term outcome tracking given limited clinical experience with state-regulated psilocybin programs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.